SEC Form 4 · accession 0001553878-17-000068
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Officer — Chief Executive Officer · Director
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 15, 2017 | M | 74,000 | $31.39 | A | 223,710 | D | |
| Common StockF2 | Nov 15, 2017 | S | 22,460 | $125.544 | D | 201,250 | D | |
| Common StockF3 | Nov 15, 2017 | S | 28,399 | $126.603 | D | 172,851 | D | |
| Common StockF4 | Nov 15, 2017 | S | 7,120 | $127.54 | D | 165,731 | D | |
| Common StockF5 | Nov 15, 2017 | S | 10,571 | $128.484 | D | 155,160 | D | |
| Common StockF6 | Nov 15, 2017 | S | 4,850 | $129.57 | D | 150,310 | D | |
| Common StockF7 | Nov 15, 2017 | S | 600 | $130.218 | D | 149,710 | D | |
| Common StockF8 | holding | — | — | — | 2,960 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9,F1 | $31.39 | Nov 15, 2017 | M | 74,000 | D | — | Dec 12, 2017 | Common Stock | 74,000 | 73,415 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017.
- F2Sale prices ranged from $125.07 to $126.05.
- F3Sale prices ranged from $126.08 to $127.05.
- F4Sale prices ranged from $127.08 to $128.06.
- F5Sale prices ranged from $128.09 to $129.08.
- F6Sale prices ranged from $129.11 to $130.00.
- F7Sale prices ranged from $130.15 to $130.41.
- F8The reporting person owns 2,960 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F9The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.